RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER
Contact:
NCT Number:
Protocol:
AAAR9954
Study Status:
Active/Enrolling
Population:
Adult
Phase:
NA
The purpose of this study is to determine if overall survival of patients monitored with serum tumor marker direct disease monitoring (STMDDM) is as good as the overall survival of patients monitored with the usual care.
Are you Eligible? (Inclusion Criteria)
- Do you have hormone positive, HER-2 negative, metastatic breast cancer?
- Are you 18 years of age or older?
- Are you willing to be monitored for your disease for the duration of this study?
Specialty Area(s)
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032